- CERo Therapeutics (CERO, Financial) announces key clinical trial site at Colorado Blood Cancer Institute for its Phase 1 trial of CER-1236 in AML.
- Initial patient dosing for CER-1236 expected by June, with enrollment currently underway.
- The trial addresses patients with acute myeloid leukemia (AML), including those with TP53 mutations, relapsed/refractory disease, and measurable residual disease.
CERo Therapeutics Holdings, Inc. (CERO), a company focused on advancing innovative immunotherapy solutions, has announced the selection of Sarah Cannon Research Institute at Colorado Blood Cancer Institute (CBCI) as a key site for its Phase 1 clinical trial of CER-1236, targeting acute myeloid leukemia (AML). The trial aims to evaluate the safety and preliminary efficacy of the treatment in patients with relapsed/refractory AML, measurable residual disease, or TP53 gene mutation.
This first-in-human, multi-center study comprises a two-part structure, beginning with dose escalation to identify the highest tolerated dose, followed by an expansion phase to further assess safety and efficacy. Key outcomes being monitored include adverse events, dose-limiting toxicities, and response rates. Currently, patient enrollment is progressing well, with initial dosing anticipated by June 2025.
The CBCI, which serves a seven-state region and is a recognized leader in blood cancer care, will significantly bolster the trial's recruitment efforts. The study leverages a novel chimeric engulfment receptor technology, designed to enhance treatment efficacy and reduce relapse rates among AML patients.
Chris Ehrlich, CEO of CERo Therapeutics, highlighted the importance of this partnership: "CBCI's involvement is a testament to the scientific rigour of our work with CER-1236. We look forward to advancing this trial and are enthusiastic about the potential impact of our proprietary technology in treating AML and possibly expanding our research into solid tumors in the future."
